Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life-threatening diseases. The company is headquartered in Hayward, California and currently employs 21 full-time employees. The company went IPO on 2010-03-02. The firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.
Follow-Up Questions
Anthera Pharmaceuticals Inc의 CEO는 누구입니까?
Mr. J. Craig Thompson은 2016부터 회사에 합류한 Anthera Pharmaceuticals Inc의 President입니다.
ANTH 주식의 가격 성능은 어떻습니까?
ANTH의 현재 가격은 $0.0001이며, 전 거래일에 decreased 0% 하였습니다.
Anthera Pharmaceuticals Inc의 주요 사업 주제나 업종은 무엇입니까?
Anthera Pharmaceuticals Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
